Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
4.720
-0.120 (-2.48%)
At close: Aug 1, 2025, 4:00 PM
4.710
-0.010 (-0.21%)
After-hours: Aug 1, 2025, 7:45 PM EDT
Cellectar Biosciences Employees
Cellectar Biosciences had 11 employees as of December 31, 2024. The number of employees decreased by 9 or -45.00% compared to the previous year.
Employees
11
Change (1Y)
-9
Growth (1Y)
-45.00%
Revenue / Employee
n/a
Profits / Employee
-$2,231,227
Market Cap
13.49M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11 | -9 | -45.00% |
| Dec 31, 2023 | 20 | 5 | 33.33% |
| Dec 31, 2022 | 15 | 3 | 25.00% |
| Dec 31, 2021 | 12 | 1 | 9.09% |
| Dec 31, 2020 | 11 | 3 | 37.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CLRB News
- 4 weeks ago - Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option - GlobeNewsWire
- 4 weeks ago - Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering - GlobeNewsWire
- 5 weeks ago - Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement - GlobeNewsWire
- 5 weeks ago - Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC) - GlobeNewsWire
- 6 weeks ago - Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split - GlobeNewsWire
- 7 weeks ago - Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma - GlobeNewsWire
- 2 months ago - Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM) - GlobeNewsWire